4Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
6Ostrosky-Zeichner L,Alexander BD,Kett DH,et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.Clin Infect Dis,2005,41:654-659.
7Food and Drug Administration,HHS.Class Ⅱ Special Controls Guidance Document:serological assays for the detection of betaglucan.Fed Reqist,2004,69:56934-56936.
8Mandell LA,Marrie TJ,Grossman RF,et al.Canadian guidelines for the initial management of community-acquired pneumonia:an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.The Canadian CommunityAcquired Pneumonia Working Group.Clin Infect Dis,2000,31:383-421.
9Woodhead M,Blasi F,Ewig S,et al.Guidelines for the management of adult lower respiratory tract infections.Eur Respir J,2005,26:1138-1180.
10Mandell LA,Bartlett JG,Dowell SF,et al.Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Clin Infect Dis,2003,37:1405-1433.
3Aliberti S,Blasi F. The management of patients with communi-ty-acquired pneumonia beyond antibiotic therapy[J].{H}European Journal of internal medicine,2012,(05):389-390.
4Yamamoto Y,Watanabe A,Goto H. Nationwide,multicenter survey on the efficacy and safety of piperacillin for adult commu-nity-acquired pneumonia in Japan[J].{H}Journal of Infection and Chemotherapy,2012,(04):544-551.
5Fujita J,Niki Y,Kadota J,et al.Clinical and bac;teriological efficacies of sitafloxacin against community-acquired pneumonia caused by streptoc;oc;c;us pneumoniae:nested cohort within a multicenter clinical trial[J].J In Iect Chemother,2013,19(3):472-479.
